Virax Biolabs' CEO James Foster Issues Letter to Shareholders
LONDON and DUBAI, UAE , June 14, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced that Mr. James Foster, Chairman of the Board & Chief Executive Officer of Virax, has issued a letter to shareholders.
- LONDON and DUBAI, UAE , June 14, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced that Mr. James Foster, Chairman of the Board & Chief Executive Officer of Virax, has issued a letter to shareholders.
- Results will then be delivered directly to an individual through our ViraxImmune™ Mobile Application, providing them an immune profile for a number of viruses.
- We are using COVID-19 as our first target for the in vitro diagnostic T-Cell tests to prove the effectiveness of our technology.
- This will then allow us to adapt to additional pathogens, whether variants of existing pathogens or new ones, as they emerge.